Project - THEKNEO

DIPARTIMENTO DI SCIENZE E BIOTECNOLOGIE MEDICO CHIRURGICHE

ElectromagneTic tHErapy KNEe Osteoarthritis

SAPIENZA UNIVERSITÀ DI ROMA

Effect of non-thermal radiofrequency pulsed and focalized electromagnetic field on knee osteoarthritis
Project responsibles: Fabrizio Vitullo, Mariano Serrao





В

Objectives - Effect of electromagnetic field therapy on reduction in pain, stiffness, and ADL autonomy; cartilage degeneration, oedema and sclerosis of subchondral bone; walking performance







- Size: di 1 x 60mm; 1 x 100mm; 1 x 80mm (pair)
- o Maximal power: 350 W
- Frequency of emission: 1,8 MHz/2,0 MHz



- Artificial intelligence algorithms
- self-calibration
- Target area detection

Patients with osteoarthritis (OA)

C

Preliminary results (case series) - Post-treatment MRIs show reduction of subcondral bone and periarticular edema and an increased cartilage thickness indicating regeneration

Case 1

- Age and gender: 68 years old man.
- History and symtpoms: many years of knee pain, recurrent swelling and stiffness, difficulty in moving the joint
- Cherc-therapy effect: pain reduction, Womac and KOOS scores reduction.

Pre-treatment

Post-treatment (4 months)








- Age and gender: 50 years old man
- History and symptoms; knee pain during walking in the last six months. Mild stiffness sensation without swelling and functional limitation.

Case 2

Cher-Therapy effect: pain relief, WOMAC and KOOS scores reductions









- · Age and gender: 53 years old man.
- History and symptoms: pain, stiffness and mild recurrent swelling in the last 2 years.

Case 3

Cher-Therapy effect: pain reduction, WOMAC and KOOS scores reductions







Participants

Ambulatory, community-dwelling adults, age 50-80 years old with disability due to knee osteoarthritis

Inclusion criteria

Mild to moderate radiographic medial tibiofemoral osteoarthritis (Kellgren-Lawrence score, 2 or 3)..

Excluson criteria

Severe patellofemoral EO; cognitive deficit..

CercTherapy® 8-week treatment

Clinical and instrumental assessment



T1



TO **Primary outcomes** NRS, WOMAC, KOOS

Secondary outcomes

G-walk, MRI (MOAKS) measures